TY  - JOUR
A1  - Weber, J.
A1  - Glutsch, V.
A1  - Geissinger, E.
A1  - Haug, L.
A1  - Lock, J.F.
A1  - Schneider, F.
A1  - Kneitz, H.
A1  - Goebeler, M.
A1  - Schilling, B.
A1  - Gesierich, A.
T1  - Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
JF  - British Journal of Dermatology
N2  - The introduction of new therapeutic agents has revolutionized the treatment of metastatic melanoma. The approval of adjuvant anti‐programmed death‐1 monotherapy with nivolumab or pembrolizumab, and dabrafenib plus trametinib has recently set a new landmark in the treatment of stage III melanoma. Now, clinical trials have shown that immune checkpoint blockade can be performed in a neoadjuvant setting, an approach established as a standard therapeutic approach for other tumour entities such as breast cancer. Recent studies suggest that a pathological response achieved by neoadjuvant immunotherapy is associated with long‐term tumour control and that short neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy. Most recently, neoadjuvant ipilimumab plus nivolumab in stage III melanoma was reported. With two courses of dose‐optimized ipilimumab (1 mg kg−1) combined with nivolumab (3 mg kg−1), pathological responses were observed in 77% of patients, while only 20% of patients experienced grade 3 or 4 adverse events. However, the neoadjuvant trials employing combined immune checkpoint blockade conducted so far have excluded patients with in transit metastases, a common finding in stage III melanoma. Here we report four patients with in transit metastases or an advanced primary tumour who have been treated with neoadjuvant ipilimumab plus nivolumab according to the OpACIN‐neo trial scheme (arm B). All patients achieved radiological disease control and a pathological response. None of the patients has relapsed so far.
KW  - Immunotherapy
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-213520
VL  - 183
IS  - 3
ER  - 
TY  - JOUR
A1  - Ellgring, Johann Heinrich
A1  - Schneider, F.
A1  - Friedrich, J.
A1  - Fus, I.
A1  - Beyer, T.
A1  - Heimann, H.
A1  - Himer, W.
T1  - The effects of neuroleptics on facial action in schizophrenic patients
N2  - This paper describes the influence of neuroleptic therapy on facial action in drug-naive schizophrenics. In a comparative study of medicated and unmedicated schizophrenic patients, the coordinates of 12 small light-reflecting points, attached to subjects' faces, were computer-recorded and analyzed automatically during a semistandardized clinical interview. In addition, facial activity in videotaped interviews was coded using the Facial Action Coding System (FACS). Each sample group comprised of eight patients with the DSMIII- R diagnostic criteria "schizophrenia" or "schizophreniform disorder". Subjects were studied on two occasions, one shortly after admission to the hospital, the other three weeks later. Group I was unmedicated during the first session, whereas group2 was medicated throughout the study. Three weeks after the start of medication, at the second interview, both recording methods showed a reduction in facial activity and facial expression across all subjects in group 1. The facial action of patients in group2, however, remained unchanged.
N2  - Ziel der vorliegenden Arbeit war die Untersuchung des Einflusses von Neuroleptika auf die Mimik von unmedizierten schizophrenen Patienten. Wiihrend eines halbstandardisierten klinischen Interviews worde die Beweglichkeit von zwolf kleinen, licht-reflektierenden Punkten, die in das Gesicht von medizierten und unmedizierten schizophrenen Patienten geklebt worden, automatisch im Zeitverlauf gemessen. Erganzend wurde der mirnische Ausdruck mit dem Facial Action Coding System (FACS) kodiert, wofiir die Patienten gleichzeitig mit Video aufgenommen worden. Jede der beiden Gruppen bestand aus acht Patienten mit den DSM-IIIR- Diagnosen "Schizophrenie" oder "Schizophrenieforme Storung". Die Patienten worden einmal direkt nach der stationaren Aufnahme und ein zweites Mal nach drei Wochen untersucht. Die Patienten der ersten Gruppe waren zum ersten Zeitpunkt nicht mit Neuroleptika mediziert, wiihrend die der zweiten Gruppe schon zu diesem Zeitpunkt entsprechende Medikamente einnahmen. Es konnte eine Reduktion der mimischen Beweglichkeit des gesamten Gesichtes im Sinne einer neuroleptisch bedingten Hypornimie der primiir Neuroleptika-unbehandelten Patienten bei der zweiten Untersuchung beobachtet werden. Die andere Gruppe Schizophrener, die zu beiden Zeitpunkten mit Neuroleptika behandelt waren, zeigte keine Veriinderung in ihrer mimischen Beweglichkeit.
Y1  - 1992
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-43269
ER  -